BWA
ARQT icon

Basecamp Wealth Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Basecamp Wealth Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$94 – 1832
2026
Q1 		$94 Buy
+4
New +$102 ﹤0.01% 1938

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Basecamp Wealth Advisors's ARQT Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 4 shares — an estimated $94 sold.

Basecamp Wealth Advisors first reported a position in ARQT in Q1 2026 and held it in 1 quarter. The position peaked at $94 in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Basecamp Wealth Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 4 Arcutis Biotherapeutics shares in Q2 2026, an estimated $94.
  • Basecamp Wealth Advisors first reported a position in Arcutis Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Arcutis Biotherapeutics position peaked at $94 in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.